Antiviral Treatment Alters the Frequency of Activating and Inhibitory Receptor-Expressing Natural Killer Cells in Chronic Hepatitis B Virus Infected Patients

Table 2

Virological outcomes to tenofovir or adefovir.

Time point	TDF	ADV
Baseline	8.01 (6.22–9.22)	7.81 (5.89–8.86)
4 weeks	5.16 (2.91–6.77)*	4.58 (2.79–6.33)*
8 weeks	2.95 (2.34–5.98)*	3.58 (1.89–5.96)^*#
12 weeks	2.42 (1.62–5.47)*	2.83 (1.88–5.63)*
24 weeks	1.85 (1.3–4.8)*	2.21 (1.3–5.57)*

Compare with the initial of the treatment, *P < 0.05; compare with two drugs, ^#P < 0.05.